- Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: olodaterol; Drug: olodaterol; Drug: Tiotropium; Drug: Tiotropium; Drug: Oldaterol; Drug: Tiotropium + olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: olodaterol; Drug: tiotropium; Drug: tiotropium + olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: HIV-1-Associated Cognitive Motor Complex
Intervention:
Sponsors: Holdsworth House Medical Practice; Holdsworth House Medical Practice
Recruiting - verified November 2011 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012 - Condition: Pulmonary Fibrosis
Interventions: Drug: placebo; Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Peripheral Arterial Disease
Interventions: Drug: Niacin/Laropiprant combination; Drug: Sugar pill
Sponsors: Bayside Health; Bayside Health; National Health and Medical Research Council, Australia
Recruiting - verified July 2011 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera]; Drug: rituximab [MabThera]; Drug: rituximab [MabThera]; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Pulmonary Disease, Chronic Obstructive; Cardiovascular Disease
Interventions: Drug: fluticasone furoate/vilanterol; Drug: fluticasone furoate; Drug: vilanterol; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Castleman's Disease
Interventions: Drug: Placebo; Drug: CNTO 328
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: rituximab; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech; German CLL Study Group
Recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium +salmeterol+ fluticasone high dose; Drug: Tiotropium+salmeterol+ fluticasone high,med, low, placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
 |
Join Clinical Trials for Chronic Illness in Australia |
